Superworth

Relmada Therapeutics price to book ratio RLMD

Market value divided by the book value of the company's net assets, since 2015.

Today, Oct 23, 2026
1.7×
10-year median
0.9×
Against its 10-year history
73rd
percentile: 0 is its lowest day, 100 its highest
10-year range
0.1× to 45.8×
Peer median
1.9×

Relmada Therapeutics' price to book ratio is 1.7× as of Oct 23, 2026.

That is above its ten-year median of 0.9×, higher than on 73% of days in the last ten years.

Over that time it ranged from 0.1× in Mar 2023 to 45.8× in Mar 2026.

The median for 10 large drugmakers of a similar size is 1.9×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far1.7×1.6×45.8×
202534.9×0.2×34.9×
20240.2×0.2×0.5×
20230.3×0.1×0.3×
20220.2×0.1×1.2×
20211.1×0.8×1.4×
20200.9×0.8×16.8×
201913.4×2.7×40.7×
20185.2×1.2×5.6×
20171.3×0.4×1.6×
20160.5×0.2×0.7×
20150.4×0.4×8.5×

Against its peers

Companies in Drug Manufacturers - General nearest Relmada Therapeutics' size, closest first, today.

CompanyPrice to book ratio
RLMDRelmada Therapeutics1.7×
ARVNArvinas0.8×
PBYIPuma Biotechnology4.1×
NATRNatures Sunshine Products1.3×
IRWDIronwood Pharmaceuticalsn/m
ZVRAZevra Therapeutics2.7×
CRMDCorMedix1.3×
COLLCollegium Pharmaceutical2.4×
ABUSArbutus Biopharma3.2×
AMPHAmphastar Pharmaceuticals1.4×
OMEROmerosn/m
Peer median1.9×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Relmada Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.